乳腺癌保乳手术的安全切缘

doi:10.3760/cma.j.issn.1673-422X.2016.06.016

摘要/Abstract

摘要： 保乳手术现已成为早期乳腺癌的首选治疗手段，但安全切缘仍然是困扰着外科医生实施保乳手术的重要问题之一。由于多种临床因素对安全切缘存在一定的影响，目前对保乳手术安全切缘并未达成相关共识，存在一定的争议。

Abstract: Breast conserving surgery has become the first choice for the treatment of early breast cancer. However, the safety margin is still one of the important issues for surgeons in the implementation of breast conserving surgery. Because variety of clinical factors have some effects on the safety margin, at present, no consensus on safe margin of breast conserving surgery is reached, and the controversy still goes on.

Key words: Breast neoplasms, Mastectomy, Margin width

许睿，钱军. 乳腺癌保乳手术的安全切缘[J]. 国际肿瘤学杂志, 2016, 43(6): 458-461.

Xu Rui, Qian Jun. Safe margin of breast conserving surgery for breast cancer[J]. Journal of International Oncology, 2016, 43(6): 458-461.

参考文献

［1］ Fisher B, Anderson S, Bryant J, et al. Twentyyear followup of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer［J］. N Engl J Med, 2002, 347(16): 1233-1241. DOI: 10.1056/NEJMoa022152 ［2］ McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery［J］. JAMA, 2012, 307(5): 467-475. DOI: 10.1001/jama.2012.43. ［3］ Biglia N, Ponzone R, Bounous VE, et al. Role of reexcision for positive and close resection margins in patients treated with breastconserving surgery［J］. Breast, 2014, 23(6): 870-875. DOI: 10.1016/j.breast.2014.09.009. ［4］ Houssami N, Macaskill P, Marinovich ML, et al. Metaanalysis of the impact of surgical margins on local recurrence in women with earlystage invasive breast cancer treated with breast conserving surgery［J］. Eur J Cancer, 2010, 46(18): 3219-3232. DOI: 10.1016/j.ejca.2010.07.043. ［5］ Behm EC, Beckmann KR, Dahlstrom JE, et al. Surgical margins and risk of locoregional recurrence in invasive breast cancer: an analysis of 10year data from the Breast Cancer Treatment Quality Assurance Project［J］. Breast, 2013, 22(5): 839-844. DOI: 10.1016/j.breast.2013.02.018. ［6］ Dillon MF, Hill AD, Quinn CM, et al. A pathologic assessment of adequate margin status in breastconserving therapy［J］. Ann Surg Oncol, 2006, 13(3): 333-339. DOI: 10.1245/ASO.2006.03.098 ［7］ Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breastconserving surgery? Surgeon attitudes and correlates［J］. Ann Surg Oncol, 2010, 17(2): 558-563. DOI: 10.1245/s10434-009-0765-1. ［8］ Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical OncologyAmerican Society for Radiation Oncology consensus guideline on margins for breastconserving surgery with wholebreast irradiation in stages Ⅰ and Ⅱ invasive breast cancer［J］. Ann Surg Oncol, 2014, 21(3): 704-716. DOI: 10.1245/s10434-014-3481-4. ［9］ Bhatti AB, Khan A, Muzaffar N, et al. Safe negative margin width in breast conservative therapy: results from a population with a high percentage of negative prognostic factors［J］. World J Surg, 2014, 38(11): 2863-2870. DOI: 10.1007/s00268-014-2651-7. ［10］ Groot G, Rees H, Pahwa P, et al. Predicting local recurrence following breastconserving therapy for early stage breast cancer: the significance of a narrow (≤ 2 mm) surgical resection margin［J］. J Surg Oncol, 2011, 103(3): 212-216. DOI: 10.1002/jso.21826. ［11］ Gangi A, Chung A, Mirocha J, et al. Breastconserving therapy for triplenegative breast cancer［J］. JAMA Surg, 2014, 149(3): 252-258. DOI: 10.1001/jamasurg.2013.3037. ［12］ Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triplenegative breast cancer after breastconserving surgery and radiation［J］. Cancer, 2009, 115(5): 946-951. DOI: 10.1002/cncr.24094. ［13］ Bhatti AB, Khan AI, Siddiqui N, et al. Outcomes of triplenegative versus nontriplenegative breast cancers managed with breastconserving therapy［J］. Asian Pac J Cancer Prev, 2014, 15(6): 2577-2581. DOI: 10.7314/APJCP.2014.15.6.2577. ［14］ Pilewskie M, Ho A, Orell E, et al. Effect of margin width onlocal recurrence in triplenegative breast cancer patients treated with breastconserving surgery［J］. Ann Surg Oncol, 2013, 20(7): 2140-2147. DOI: 10.1245/s10434-013-3416-5. ［15］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI: 10.3322/caac.21254. ［16］ Wapnir IL, Dignam JJ, Fisher B, et al. Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B17 and B24 randomized clinical trials for DCIS［J］. J Natl Cancer Inst, 2011, 103(6): 478-488. DOI: 10.1093/jnci/djr027. ［17］ Warnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breastconserving surgery for ductal carcinoma in situ: 20 years followup in the randomized SweDCIS Trial［J］. J Clin Oncol, 2014, 32(32): 3613-3618. DOI: 10.1200/JCO.2014.56.2595. ［18］ Wai ES, Lesperance ML, Alexander CS, et al. Predictors of local recurrence in a populationbased cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone［J］. Ann Surg Oncol, 2011, 18(1):119-124. DOI: 10.1245/s10434-010-1214-x. ［19］ Zee KJ, Subhedar P, Olcese C, et al. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2 996 women treated with breastconserving surgery for 30 years［J］. Ann Surg, 2015, 262(4): 623-631. DOI: 10.1097/SLA.0000000000001454. ［20］ Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ［J］. J Clin Oncol, 2009, 27(10): 1615-1620. DOI: 10.1200/JCO.2008.17.5182. ［21］ Ciocca RM, Li T, Freedman GM, et al. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breastconserving therapy［J］. Ann Surg Oncol, 2008, 15(8): 2263-2271. DOI: 10.1200/JCO.2008.17.5182. ［22］ Sadek BT, Shenouda MN, Abi Raad RF, et al. Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is reexcision necessary?［J］. Int J Radiat Oncol, 2013, 87(4): 726-730. DOI: 10.1016/j.ijrobp.2013.08.012. ［23］ Galimberti V, Maisonneuve P, Rotmensz N, et al. Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology［J］. Ann Surg, 2011, 253(3): 580-584. DOI: 10.1097/SLA.0b013e31820d9a81. ［24］ Bartelink H, Maingon P, Poortmans P, et al. Wholebreast irradiation with or without a boost for patients treated with breastconserving surgery for earlybreast cancer: 20year followup of a randomised phase 3 trial［J］. Lancet Oncol, 2015, 16(1): 47-56. DOI: 10.1016/S14702045(14)71156-8. ［25］ Kunkler IH, Williams LJ, Jack WJ, et al. Breastconserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial［J］. Lancet Oncol, 2015, 16(3): 266-273. DOI: 10.1016/S1470-2045(14)71221-5. ［26］ Livi L, Meattini I, Franceschini D, et al. Radiotherapy boost doseescalation for invasive breast cancer after breastconserving surgery: 2 093 patients treated with a prospective margindirected policy［J］. Radiother Oncol, 2013, 108(2): 273-278. DOI: 10.1016/j.radonc.2013.02.009. [27] Anderson S, Wapnir I, Dignam J, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer[J]. J Clin Oncol, 2009, 27(15): 2466-2473. DOI: 10.1200/JCO.2008.19.8424. [28] Smith SL, Truong PT, Lu L, et al. Identification of patients at very low risk of local recurrence after breast-conserving surgery[J]. Int J Radiat Oncol Biol Phys, 2014, 89(3): 556-562. DOI: 10.1016/j.ijrobp.2014.03.016.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.